Context Therapeutics (NASDAQ:CNTX – Get Free Report) issued its quarterly earnings data on Wednesday. The company reported ($0.22) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.11) by ($0.11), Zacks reports.
Context Therapeutics Trading Down 6.7 %
NASDAQ:CNTX traded down $0.14 during trading hours on Friday, reaching $1.95. 339,093 shares of the company were exchanged, compared to its average volume of 295,287. The business has a 50 day moving average of $2.09 and a 200 day moving average of $2.06. Context Therapeutics has a 1-year low of $0.77 and a 1-year high of $2.75.
Wall Street Analysts Forecast Growth
Separately, HC Wainwright restated a “buy” rating and issued a $6.00 price target on shares of Context Therapeutics in a research note on Monday, September 23rd.
Context Therapeutics Company Profile
Context Therapeutics Inc, a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy.
Featured Stories
- Five stocks we like better than Context Therapeutics
- Are Penny Stocks a Good Fit for Your Portfolio?
- Airbnb Stock Attracts Attention With Strong Cash Flow Strategy
- Stock Analyst Ratings and Canadian Analyst Ratings
- MarketBeat Week in Review – 11/4 – 11/8
- What is an Earnings Surprise?
- Trump’s Return: Which Sectors Will Benefit Most?
Receive News & Ratings for Context Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Context Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
